Sun Pharmaceutical gains on entering into partnership with AstraZeneca Pharma India

Sun Pharmaceutical Industries Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 524715 | NSE: SUNPHARMA

23 Mar 2016 Evaluate

Sun Pharmaceutical Industries is currently trading at Rs. 848.95, up by 4.85 points or 0.57% from its previous closing of Rs. 844.10 on the BSE.

The scrip opened at Rs. 845.00 and has touched a high and low of Rs. 852.30 and Rs. 835.00 respectively. So far 145833 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1200.70 on 07-Apr-2015 and a 52 week low of Rs. 706.40 on 24-Nov-2015.

Last one week high and low of the scrip stood at Rs. 852.30 and Rs. 799.00 respectively. The current market cap of the company is Rs. 203512.96 crore.

The promoters holding in the company stood at 54.97% while Institutions and Non-Institutions held 35.25% and 9.77% respectively.

Sun Pharmaceutical Industries has entered into partnership with the AstraZeneca Pharma India for the distribution of dapagliflozin, an innovative Type 2 diabetes medicine, in India. Dapagliflozin is AstraZeneca India’s leading diabetes medicine.

Under the agreement, the company will promote and distribute dapagliflozin under the brand name ‘Oxra’. AstraZeneca India markets dapagliflozin under the brand name ‘Forxiga’ and under the terms of the agreement, both companies will promote, market & distribute dapagliflozin in India under different brand names. AstraZeneca will retain the intellectual property rights to dapagliflozin.

The company will also gain the rights to promote and distribute the combination of dapagliflozin with metformin under the brand name ‘Oxramet’, following regulatory approval. AstraZeneca India is currently seeking approval from the Drug Controller General of India for the combination of dapagliflozin with metformin.

Sun Pharma is world's fifth largest specialty generic and India's top pharmaceutical company. With a vertically integrated business, economies of scale, an extremely skilled team enabling delivery of quality products at affordable prices and trusted by customers and patients in over 150 countries globally. The company's global presence is supported by 49 manufacturing facilities spread across 6 continents, R&D centres worldwide and a multi-cultural workforce representing more than 50 nationalities.

Sun Pharma. Inds. Share Price

1904.65 33.10 (1.77%)

03-Jul-2026 16:59 View Price Chart

Peers

Company Name	CMP
Sun Pharma. Inds.	1904.65
Dr. Reddys Labs.	1374.55
Cipla	1458.45
Zydus Lifesciences	1141.00
Lupin	2476.10
View more..

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.